Navigation Links
Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
Date:10/22/2008

SAN DIEGO, Oct. 22 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the BIOCOM Investor Conference on October 28, 2008 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) at the Hyatt Regency Hotel in La Jolla, California. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide an overview of the company, including its clinical development and discovery programs.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at http://www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Stateme
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
4. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
5. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
6. ThreeWire Expands Presence in the Pharmaceutical Arena
7. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
8. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
9. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
11. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014   BioLife Solutions , Inc. ... and marketer of proprietary clinical grade hypothermic storage ... precision thermal shipping products for cells and tissues  ... hold its 2015 Annual Meeting of Stockholders on May ... expected date for the Annual Meeting represents a change ...
(Date:12/24/2014)... 2014 On Friday, December 19, ... the Omnibus and Continuing Resolution Appropriations Act of ... a condition eligible to receive funding through the ... the Department of Defense (DoD). The Hydrocephalus Association ... Capitol Hill, is celebrating this victory for the ...
(Date:12/24/2014)... December 23, 2014 Pipette.com announces their ... Twitter followers can submit their #HolidayInTheLab pictures for a ... lab mates. , For those struggling to think of ... Pipette.com Holiday in the Lab Contest provides the ideal ... followers to send pictures of their chemistree, holiday ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... Wis. - Its not news that Wisconsin trails national ... whys of it are broken down and detailed in ... Venture Capital published by NorthStar Economics, Inc. The ... capital for Wisconsin companies. , ,The Wisconsin Technology Network ...
... Bays Nsight Telservices (www.nsighttel.com) in 2001 as Vice President ... as Chief Technical Officer (CTO) of Chicago startup BidBuyBuild. ... NET Cable, and NetNet and heads up the company's ... deployment. , , WTN: How did your dot-com ...
... more difficult challenges in business is turning around a sick ... the company is forced into bankruptcy. Realizing the painful reality ... impossible for owners and senior executives to deal with truthfully. ... them, and they will close that big outstanding proposal, and ...
Cached Biology Technology:Growing Venture Capital in Wisconsin 2Growing Venture Capital in Wisconsin 3Interview: WTN Gets Real with Appletons Brad Hansen - Dot-Com Experience helps Executive to Spot Trends 2Interview: WTN Gets Real with Appletons Brad Hansen - Dot-Com Experience helps Executive to Spot Trends 3Turning Around a Sick Company 2
(Date:12/19/2014)... VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ... new funding to expand its team and bring LaunchKey ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the ... APAC Region 2015-2019"  report to their offering. ... market is advances in technology. With continuous advances ... solutions to the latest standard that meets the ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... you are overweight and pregnant, your baby isn,t destined to ... research report published online in The FASEB Journal ... show that modifying fat intake during pregnancy to a moderate ... mother,s size. Specifically, they found that a protein called "SIRT1" ...
... This release is available in Spanish . ... United States as a source of sugar for syrup and ... make it uniquely suited to production as a bioenergy crop, ... an ideal candidate because of its drought tolerance, adaptability to ...
... industry are excellent sources of proteins and healthy oils ... moment these side streams are mainly used as fish ... waste. Coordinated by VTT, the APROPOS (Added value ... project seeks to enrich several co-stream components at once ...
Cached Biology News:Eating well during pregnancy reduces baby's obesity risk regardless of mom's size 2Sorghum eyed as a southern bioenergy crop 2Food industry's high-quality co-streams used effectively as raw material for new products 2
100 g monoclonal antibody which can immunocapture ~10 g of Complex IV from heart mitochondria. Also included are 2 mg of bovine heart mitochondria for control immunocapture....
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Rabbit polyclonal to GPR56 ( Abpromise for all tested applications). entrezGeneID: 9289 SwissProtID: Q9Y653...
Annexin V Binding Buffer, 10X Concentrate Buffer , 50 ml Consult technical datasheet for details....
Biology Products: